William Cain, MD
Allergy & Immunology · Hermitage, TNNPI 1821083973
Payments from drug & device makers
Across 500 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Sanofi$1K
- GSK$1K
- CSL Behring$621
- Novartis$522
- Regeneron Healthcare Solutions, Inc.$512
- plus $3K from 27 others
What the payments were for
- Consulting fees$150%
- Food & beverage$9,816100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 127 | $2,686 |
| Sanofi | 50 | $1,192 |
| GSK | 65 | $1,083 |
| CSL Behring | 34 | $621 |
| Novartis | 28 | $522 |
| Regeneron Healthcare Solutions, Inc. | 22 | $512 |
| Pfizer | 22 | $386 |
| Genentech USA, Inc. | 14 | $279 |
| Optinose US, Inc. | 13 | $277 |
| ARS Pharmaceuticals Operations, Inc. | 20 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $255 |
| Octapharma USA, Inc. | 8 | $234 |
| Teva Pharmaceuticals USA, Inc. | 18 | $232 |
| Amgen | 9 | $180 |
| Grifols USA, LLC | 8 | $168 |
| Kaleo, Inc. | 9 | $152 |
| Boehringer Ingelheim | 7 | $120 |
| Hikma Pharmaceuticals USA | 6 | $102 |
| Atricure, Inc. | 1 | $100 |
| Biocryst US Sales Co., LLC | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 3 | $65 |
| Mylan Specialty L.p. | 4 | $63 |
| Alk-abello, Inc | 3 | $53 |
| Pharming Healthcare, Inc. | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $17 |
| ADMA Biomanufacturing LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,851 in reported general payments places this provider in the 65th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 159 | $383,141 |
| FasenraBenralizumab | 15 | $83,420 |
| NucalaMepolizumab | 22 | $76,894 |
| Dupixent PenDupilumab | 12 | $46,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $28,105 |
| Arnuity ElliptaFluticasone Furoate | 50 | $18,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $17,011 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $16,035 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,726 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $9,414 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,937 |
| Epinephrine | 28 | $6,669 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $6,527 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,707 |
| DuleraMometasone/Formoterol | 13 | $5,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $1,083 | $139,304132 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $2,686 | $107,36858 claims |
| Boehringer IngelheimSpiriva Respimat | $120 | $9,72617 claims |
| Hikma Pharmaceuticals USAEpinephrine | $102 | $6,66928 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $232 | $6,52711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Hermitage
- Megan StaufferHermitage$8K
- Nicholas KolinskyKnoxville$472K
- Karthik KrishnanMaryville$410K
- Tidence PrinceMaryville$303K
- Jay LiebermanMemphis$270K
- Katherine CahillNashville$208K
- Tammy Heinly McCulleyGermantown$165K
- Phillip LiebermanMemphis$131K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.